Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Keane PA, Sadda SR. Development of anti-VEGF therapies for intraocular use: a guide for clinicians. J Ophthalmol. 2012;2012:1–13.
2. Bates A, Power CA. Goliath: the structure, function, and clinical prospects of antibody fragments. Antibodies. 2019;8:28.
3. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019; pii: S0161-6420(18)33018-5.
4. Kholodenko RV, Kalinovsky DV, Doronin II, Ponomarev ED, Kholodenko IV. Antibody fragments as potential biopharmaceuticals for cancer therapy: success and limitations. Curr Med Chem. 2019;26:396–426.
5. Amadio M, Govoni S, Pascale A. Targeting VEGF in eye neovascularization: what’s new? Pharmacol Res. 2016;103:253–69.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献